Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.35 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7995038 | 1.00 | CA2 (0.38) | CA2CA12CA1CA9CHKA | |
| Acetic Acid SCHEMBL3415860 | 0.94 | KMT2A (0.36) | CA2CA12CA1CA9CHKA | |
| Hypophosphorous Acid SCHEMBL5002567 | 0.92 | CA2 (0.33) | CA2CA12CA1CA9CHKA | |
| SCHEMBL8038159 | 0.87 | PHGDH (0.33) | CA2CA12CA1CA9 | |
| SCHEMBL8040372 | 0.85 | KDM4E (0.41) | ALDH1A1HSD17B10 | |
| SCHEMBL6014037 | 0.85 | — | — | |
| SCHEMBL9693868 | 0.84 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL4580801 | 0.84 | CA2 (0.32) | CA2CHKASIGMAR1 | |
| SCHEMBL28434277 | 0.82 | SIGMAR1 (0.39) | SIGMAR1HSD17B10KDM5CKDM4C | |
| SCHEMBL8993114 | 0.80 | KDM4E (0.39) | SIGMAR1TSHRPOLBALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090087381-A1 | CHELATOR-FUNCTIONALIZED NANOPARTICLES | GENERAL ELECTRIC COMPANY (US) | 2009-04-02 | — | — | US | claimed |
| US-5674470-A | Method for imaging mammalian tissue using 1-substituted- 4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs | BRACCO DIAGNOSTICS INC. (US) | 1997-10-07 | — | — | US | claimed |
| US-5133956-A | Radiolabeled metal-binding protein for the treatment of arthritis | THE DOW CHEMICAL COMPANY (US) | 1992-07-28 | — | — | US | claimed |
| EP-0232751-B1 | 1-SUBSTITUTED-4,7,10-TRISCARBOXYMETHYL-1,4,7,10-TETRAAZACYCLODODECANE AND ANALOGS | E.R. Squibb & Sons, Inc. (US) | 1991-09-11 | — | — | EP | claimed |
| US-4885363-A | RADIOPHARMACEUTICAL IMAGING; MEDICAL DIAGNOSIS | E. R. SQUIBB & SONS, INC. (US) | 1989-12-05 | — | — | US | claimed |
| EP-0292689-A2 | Substituted 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclo-dodecane and analogs | BRACCO INTERNATIONAL B.V. (NL) | 1988-11-30 | — | — | EP | claimed |
| EP-0232751-A1 | 1-substituted-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs | E.R. Squibb & Sons, Inc. (US) | 1987-08-19 | — | — | EP | claimed |
| WO-2025226970-A2 | LY6G6D BINDING PROTEINS, NUCLEIC ACIDS ENCODING SUCH PROTEINS, AND METHODS FOR THE PREPARATION AND USE THEREOF | CARTOGRAPHY BIOSCIENCES, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12227527-B2 | Process for the preparation of 2,2′,2″-(10-((2R,3S)-1,3,4-trihydroxy butan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid and its complexes | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) | 2025-02-18 | — | — | US | disclosed |
| US-20240053349-A1 | COMPOSITIONS, IMAGING, AND THERAPEUTIC METHODS TARGETING FOLATE RECEPTOR 1 (FOLR1) | INDI MOLECULAR, INC. | 2024-02-15 | — | — | US | disclosed |
| US-11733246-B2 | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (FOLR1) | INDI MOLECULAR, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4083026-A1 | PROCESS FOR THE PREPARATION OF 2,2',2''-(10-((2R,3S)-1,3,4-TRIHYDROXY BUTAN-2-YL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIYL) TRIACETIC ACID AND ITS COMPLEXES | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2022-11-02 | — | — | EP | disclosed |
| US-20220229066-A1 | COMPOSITIONS, IMAGING, AND THERAPEUTIC METHODS TARGETING FOLATE RECEPTOR 1 (FOLR1) | INDI MOLECULAR, INC. | 2022-07-21 | — | — | US | disclosed |
| US-4889931-A | TREATING MANGANESE OXIDE WITH CHELATING AGENTS | SALUTAR, INC. (US) | 1989-12-26 | — | — | US | disclosed |
| US-4885363-A | RADIOPHARMACEUTICAL IMAGING; MEDICAL DIAGNOSIS | E. R. SQUIBB & SONS, INC. (US) | 1989-12-05 | — | — | US | disclosed |
| JP-S6452764-A | 1-SUBSTITUTED 1,4,7-TRISCARBOXYMETHYL-1,4,7,10- TETRAAZACYCLODODECANE AND ANALOGUE | SQUIBB & SONS INC | 1989-02-28 | — | — | JP | disclosed |
| EP-0292689-A2 | Substituted 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclo-dodecane and analogs | BRACCO INTERNATIONAL B.V. (NL) | 1988-11-30 | — | — | EP | disclosed |
| EP-0292689-A2 | Substituted 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclo-dodecane and analogs | BRACCO INTERNATIONAL B.V. (NL) | 1988-11-30 | — | — | EP | disclosed |
| EP-0232751-A1 | 1-substituted-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs | E.R. Squibb & Sons, Inc. (US) | 1987-08-19 | — | — | EP | disclosed |
| EP-0232751-A1 | 1-substituted-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs | E.R. Squibb & Sons, Inc. (US) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220229066-A1 | COMPOSITIONS, IMAGING, AND THERAPEUTIC METHODS TARGETING FOLATE RECEPTOR 1 (FOLR1) | FOLR1, FOLR2, FOLH1 | CA2 3908/4885CA12 1581/4885CA1 2291/4885 |
| US-20240053349-A1 | COMPOSITIONS, IMAGING, AND THERAPEUTIC METHODS TARGETING FOLATE RECEPTOR 1 (FOLR1) | FOLR1, FOLR2, FOLH1 | CA2 3908/4885CA12 1581/4885CA1 2291/4885 |
| US-12227527-B2 | Process for the preparation of 2,2′,2″-(10-((2R,3S)-1,3,4-trihydroxy butan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid and its complexes | TMCO1, CA2, CALCA | CA2 2/4885CA12 192/4885CA1 15/4885 |
| US-20090087381-A1 | CHELATOR-FUNCTIONALIZED NANOPARTICLES | SLC40A1, TFRC, SLC19A1 | CA2 1254/4885CA12 116/4885CA1 26/4885 |
| US-11733246-B2 | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (FOLR1) | FOLR1, FOLR2, FOLH1 | CA2 3908/4885CA12 1581/4885CA1 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.